Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington. Show more
Location: 18702 North Creek Parkway, Bothell, WA, 98011, United States | Website: https://immunome.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
809.2M
52 Wk Range
$5.15 - $16.81
Previous Close
$9.30
Open
$9.23
Volume
1,179,785
Day Range
$8.46 - $9.34
Enterprise Value
496.7M
Cash
317.3M
Avg Qtr Burn
-38.17M
Insider Ownership
11.48%
Institutional Own.
83.28%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IMM-BCP-01 Details COVID-19 | Phase 1b Data readout |